Deutsche Bank AG Decreases Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Deutsche Bank AG lowered its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 0.7% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 928,970 shares of the biopharmaceutical company’s stock after selling 6,282 shares during the quarter. Deutsche Bank AG owned 1.60% of Agios Pharmaceuticals worth $27,219,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new position in Agios Pharmaceuticals during the fourth quarter valued at $39,000. CWM LLC lifted its stake in Agios Pharmaceuticals by 150.2% in the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 996 shares in the last quarter. Sterling Capital Management LLC lifted its stake in Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 1,587 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in Agios Pharmaceuticals by 16.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 499 shares during the last quarter. Finally, Summit Investment Advisors Inc. increased its stake in Agios Pharmaceuticals by 7.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company’s stock worth $194,000 after buying an additional 394 shares in the last quarter.

Insider Buying and Selling

In other news, insider Sarah Gheuens sold 11,914 shares of the firm’s stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $37.99, for a total transaction of $452,612.86. Following the completion of the sale, the insider owned 61,271 shares in the company, valued at $2,327,685.29. This trade represents a 16.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Cecilia Jones sold 1,780 shares of the company’s stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $59,701.20. Following the completion of the transaction, the chief financial officer owned 30,049 shares in the company, valued at $1,007,843.46. This represents a 5.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,448 shares of company stock worth $2,026,141 over the last ninety days. 4.93% of the stock is currently owned by insiders.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO opened at $35.38 on Wednesday. The stock’s fifty day moving average is $36.33 and its two-hundred day moving average is $32.70. The firm has a market capitalization of $2.06 billion, a P/E ratio of 3.22 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.19). Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. The firm had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.46 million. As a group, sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Scotiabank decreased their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating on the stock in a research report on Monday, July 28th. Bank of America decreased their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. Finally, Wall Street Zen cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $56.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.